Industry news
- Industry news
- Hematology
- News
Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.
Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Subscribe now for instant access to the benefits Pharmalicensing Intelligence has to offer. Find out more.
Company details
If you want to find out more about the company visit Johnson & Johnson profile.
Related reports
Market Research Reports provided by reports.iptechex.com
Feb 2011 - 73 pages - $500
Jul 2011 - 6 pages - $500
Sep 2011 - 95 pages - $500
Dec 2010 - 59 pages - $2,000
Nov 2011 - 38 pages - $3,800
May 2011 - 130 pages - $500
Nov 2010 - 270 pages - $1,495
Sep 2011 - 98 pages - $3,500
Dec 2010 - 69 pages - $1,000
Related news
Latest News
- Bayer
- Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
- YM BioSciences granted Orphan Drug Designation for CYT387
- YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
- Affymax and Takeda Announce Preliminary U.S. Registration Strategy for Investigational Drug, Hematide(TM)/Peginesatide, to Treat Anemia in Chronic Renal Failure
- The Gamida Cell-TEVA Joint Venture Receives FDA Fast Track Designation for StemEx
- More news... | RSS Feed...
Most Viewed
YM BioSciences granted Orphan Drug Designation for CYT387
The Gamida Cell-TEVA Joint Venture Receives FDA Fast Track Designation for StemEx
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us